-
Roth Capital Resumes Coverage on Halozyme Therapeutics (HALO) at Buy
-
Roth Capital Upgrades Halozyme Therapeutics (HALO) to Buy
-
Roth Capital Upgrades Halozyme Therapeutics (HALO) to Buy

